UroAlerts - Prostate Cancer Weekly

Prostate Cancer

Positive Guidance from the U.S. FDA on 64Cu-SAR-bisPSMA Phase III Trial in Patients with Recurrence of Prostate Cancer

Prognostic model for second progression-free survival and overall survival in patients with high-risk metastatic hormone-sensitive prostate cancer treated with abiraterone acetate and androgen deprivation therapy.

The prognostic role of pan-immune inflammation value in patients with metastatic castration resistance prostate cancer treated with Lutetium-177 (177Lu)-PSMA-617.

Prospective, Randomized Controlled Pivotal Trial of Biodegradable Balloon Rectal Spacer for Prostate Radiation Therapy

Five-Year Prostate-Specific Membrane Antigen Positron Emission Tomography-Based Outcomes of Spot-Scanning Proton Radiation Therapy for Localized Prostate Cancer: A Single Institution Experience

Aiming High: Prostate-specific Membrane Antigen Expression in Treatment-naïve Prostate Cancer.

The Immune Microenvironment in Prostate Cancer: A Comprehensive Review.

PSMA PET/CT for treatment response evaluation at predefined time points is superior to PSA response for predicting survival in metastatic castration-resistant prostate cancer patients

Systemic immune-inflammation index is associated with high risk for prostate cancer among the U.S. elderly: Evidence from NHANES 2001-2010.

Early Prostate-Specific Antigen Response by 6 Months Is Predictive of Treatment Effect in Metastatic Hormone Sensitive Prostate Cancer: An Exploratory Analysis of the TITAN Trial

Size and SUVmax define the contribution of nodal metastases to PSA in oligorecurrent prostate cancer.

Impact of Gene Expression Classifier Testing on Adjuvant Treatment Following Radical Prostatectomy: The G-MINOR Prospective Randomized Cluster-crossover Trial.

"I Just Had to Do What I Had to Do": Characterizing Direct and Indirect Prostate Cancer Treatment Costs for Black Survivors and Their Caregivers.

Perturbations in the blood metabolome up to a decade before prostate cancer diagnosis in 4387 matched case-control sets from the European Prospective Investigation into Cancer and Nutrition.

Methylation-based immune deconvolution in prostate cancer patients before and after radical prostatectomy.

Detection of Germline Variants in Patients with Localized and Metastatic Prostate Cancer through Guideline-Based Testing.

Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC).

Loss of PI5P4Kα slows the progression of a Pten mutant basal cell model of prostate cancer.

Post-Treatment surveillance intensity and overall survival in prostate cancer survivors (AFT-30).

Stimulating Soluble Guanylyl Cyclase with the Clinical Agonist Riociguat Restrains the Development and Progression of Castration-Resistant Prostate Cancer.

Prostate cancer and solid organ transplantation: patient management and outcomes.

Clarity enters a Clinical Manufacturing Agreement for Cu-64 SAR-bisPSMA with SpectronRx

Efficacy and Safety of Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone in the First-line Treatment of Patients with Asymptomatic/Mildly Symptomatic and Symptomatic Metastatic Castration-resistant Prostate Cancer: Analyses from the Phase 3 PROpel

Cone-Beam Computed Tomography (CBCT)-Based Online Adaptive Radiation Therapy (oART) for a Prostate Cancer Patient With Inflammatory Bowel Disease and Bilateral Total Hip Arthroplasty: A Case Report.

Treatment response assessment in mCRPC: is PSMA-PET/CT going to take the lead?

Targeted Biopsy is Sufficient for Men on Active Surveillance for Early-Stage Prostate Cancer.

A Phase I Trial of Image-Guided, Risk-Volume-Adapted Post-Prostatectomy Radiotherapy.

Rediscovering citrate as a biomarker for prostate cancer.

Efficacy and Toxicity of [177Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data.

Radiotherapy and theranostics: a Lancet Oncology Commission.

Nivolumab in patients with metastatic castration-resistant prostate cancer with and without DNA repair defects.

Testing home-based exercise strategies in underserved minority cancer patients undergoing chemotherapy (THRIVE) trial: a study protocol.

Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer.

Frequent CHD1 deletions in prostate cancers of African American men is associated with rapid disease progression.

Peripheral blood interferon responses to toll-like receptor 1/2 signaling associate with longer survival in men with metastatic prostate cancer treated with Sipleucel-T.

Proteomic and phosphoproteomic landscape of localized prostate cancer unveils distinct molecular subtypes and insights into precision therapeutics.

Setting the Stage: Feasibility and Baseline Characteristics in the PARTIQoL Trial Comparing Proton Therapy vs. IMRT for Localized Prostate Cancer.

Discovery of a Highly Potent PROTAC Degrader of p300/CBP Proteins for the Treatment of Enzalutamide-Resistant Prostate Cancer.

Synthetic Lethal Targeting of Cyclin Dependent Kinase-12-Deficient Prostate Cancer with PARP Inhibitors.

Deep Learning Features Can Improve Radiomics-Based Prostate Cancer Aggressiveness Prediction.

Coagulation factor X promotes resistance to androgen-deprivation therapy in prostate cancer.

Quantitative MRI biomarker for classification of clinically significant prostate cancer: Calibration for reproducibility across echo times.

Comparative Transcriptomes of Canine and Human Prostate Cancers Identify Mediators of Castration Resistance.

Nutrient Intakes in Prostate Cancer Survivors in the United States: A Nationally Representative Study.

Plant-based diets and urological health.

Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer.

Survival of Men with Metastatic Hormone-Sensitive Prostate Cancer and Adrenal-Permissive HSD3B1 Inheritance - Beyond the Abstract

Multiplex Imaging of Localized Prostate Tumors Reveals Altered Spatial Organization of AR-Positive Cells in the Microenvironment - Beyond the Abstract

UroAlerts - Prostate Cancer Weekly

Prostate Cancer

Login